Fig. 5: Pan-coronavirus inhibition potency of optimized GC376 analogs. | Nature Communications

Fig. 5: Pan-coronavirus inhibition potency of optimized GC376 analogs.

From: Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19

Fig. 5: Pan-coronavirus inhibition potency of optimized GC376 analogs.

a Evaluations of GC376 analogs in a cell-based SARS-CoV, SARS-CoV-2, and MERS-CoV 3CL protease inhibitor assay. Expression of viral 3CL protease suppressed the viability of the 293T cells. Inhibitors of the protease rescue cell growth and boost the amount of crystal violet cell staining which is read on an absorbance plate reader. Cells expressing EYFP were included as control. Experiments were performed in quartet. Data are plotted as the mean ± s.d., n = 4 biological replicates. Source data are provided as a Source Data file. b Ability of EB46, EB54, and NK01-63 to inhibit viral infection in cell culture.

Back to article page